Business News
Merck Obtains FDA Approval for Keytruda and Padcev Combination in Bladder Cancer Treatment
- Merck (MRK) announced that the FDA has approved the use of Keytruda and Keytruda Qlex with Padcev as an additional treatment for bladder cancer.
- This combination is intended for patients with muscle-invasive bladder cancer, initially as a neoadjuvant
